Romark Laboratories, L.C. Romark Laboratories, L.C. Romark Laboratories, L.C. Romark Laboratories, L.C. Romark Laboratories, L.C.

News & Events

News

1941 Patients Enrolled in the United States, Canada, Belgium, Australia and New Zealand

Largest Single Clinical Trial Ever Conducted for a New Drug for Acute Uncomplicated Influenza

Data to be Communicated Later in 2015

Proceeds of Senior Secured Notes Provide Capital for Construction of New Manufacturing Facility in Puerto Rico

Proceeds Used to Establish and Expand Manufacturing Capacity for the Company’s Products and for New Product Development

Clinical Trial Results Published in the Journal of Clinical Pharmacology

Study Provides Safety Data to Support New Drug Application for NT-300 in Treatment of Influenza

Company’s Chief Science Officer and Crypto Expert Urges Those Experiencing Symptoms to Consult Their Doctors for Proper Diagnosis

Contract with U.S. Department of Health and Human Services to Fund Completion of Clinical Development and Preparation for Submission of New Drug Application for NT-300

Value of Contract Increased from $44 Million to $75 Million